tradingkey.logo
tradingkey.logo
Search

Daxor Corp

DXR
Add to Watchlist
10.320USD
+0.110+1.08%
Close 07-28 16:00ETQuotes delayed by 15 min
52.22MMarket Cap
29.68P/E TTM
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+1.08%

5 Days

-1.81%

1 Month

+2.96%

6 Months

-15.48%

Year to Date

-30.03%

1 Year

+2.64%

Key Figures
11.150Open
11.150High
2.37KVolume
29.68P/E TTM
LossP/E Dynamic
--Dividend TTM
0.05%Turnover Ratio
10.210Prev. Close
10.600Low
22.58KTurnover
97.36P/E Static
1.14P/B
0.00%Div Yield TTM
5.12%ROA
14.75852wk High
1.47Volume Ratio
536.33KNet Profit
5.06MShares
0.3477EPS TTM
0.26Beta
5.26%ROE
8.07952wk Low
5.39%Amplitude
71.55%Gross Margin
52.22MMarket Cap
0.28Reward/Risk
3.53%Risk Rate

Daxor Corp News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 2 analysts
Buy
Current Rating
22.500
Target Price
+115.31%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

25
Total
5
Median
5
Average
Company name
Ratings
Analysts
Daxor Corp
DXR
2
Sixth Street Specialty Lending Inc
TSLX
12
FS KKR Capital Corp
FSK
11
SLR Investment Corp
SLRC
9
Crescent Capital BDC Inc
CCAP
8
PennantPark Floating Rate Capital Ltd
PFLT
8
1
2
3
4
5

Indicators

Indicators
Sell(2)
Neutral(4)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.031
Neutral
RSI(14)
53.319
Neutral
STOCH(KDJ)(9,3,3)
21.129
Neutral
ATR(14)
0.599
High Vlolatility
CCI(14)
62.076
Neutral
Williams %R
70.968
Sell
TRIX(12,20)
0.169
Sell
StochRSI(14)
88.044
Buy
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
10.483
Sell
MA10
10.584
Sell
MA20
10.489
Sell
MA50
10.351
Sell
MA100
10.344
Sell
MA200
11.571
Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Daxor Corp Info

Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Ticker SymbolDXR
CompanyDaxor Corp
CEOFeldschuh (Michael Richard)
Websitehttps://www.daxor.com/

Shareholders

Shareholders
Shareholders
Proportion
Joseph Feldschuh UEO
43.82%
Feldschuh (Michael Richard)
3.67%
Feldschuh (Jonathan Adam)
0.93%
Vanguard Capital Management, LLC
0.83%
Renaissance Technologies LLC
0.48%
Other
50.28%

FAQs

What is the current price of Daxor Corp (DXR)?

The current price of Daxor Corp (DXR) is 10.32.

What is the symbol of Daxor Corp?

The ticker symbol of Daxor Corp is DXR.

What is the 52-week high of Daxor Corp?

The 52-week high of Daxor Corp is 14.76.

What is the 52-week low of Daxor Corp?

The 52-week low of Daxor Corp is 8.08.

What is the market capitalization of Daxor Corp?

The market capitalization of Daxor Corp is 52.22M.

Is Daxor Corp (DXR) currently rated as Buy, Hold, or Sell?

According to analysts, Daxor Corp (DXR) has an overall rating of Buy, with a price target of 22.50.

What is the Earnings Per Share (EPS TTM) of Daxor Corp (DXR)?

The Earnings Per Share (EPS TTM) of Daxor Corp (DXR) is 1.81.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.